CLAIMS

The claims and their status in the Application are as follows:

CLAIMS

1-32. (Canceled)

33. (Withdrawn) An injectable composition comprising:

a biocompatible matrix;

radiopaque particles mixed within said biocompatible matrix, said radiopaque particles size between about 120 μ and 2200 μ; and

a contrast agent.

34. (Withdrawn) The injectable composition of claim 33, wherein said biocompatible matrix and said radiopaque particles form a slurry.

35. (Withdrawn) The injectable composition of claim 33, wherein the mixture of said biocompatible matrix and said radiopaque particles forms a hard tissue implant material.

36. (Withdrawn) The injectable composition of claim 33, wherein said radiopaque particles have a particles size between about 350μ and 2200μ.

37. (Withdrawn) The injectable composition of claim 36, further comprising radiopaque particles for contrast having a particles size between about 120 μand 350μ.

38. (Withdrawn) The injectable composition of claim 33, wherein said radiopaque particles have a particles size between about 450μ and 1600μ.

39. (Withdrawn) The injectable composition of claim 38, wherein said radiopaque particles have a particles size between about 570μ and 1150μ.

40. (Currently amended) An injectable composition comprising:

a flowable matrix;

radiopaque tracer particles in said flowable matrix, said radiopaque tracer particles having a size between about 350μ and about 2200μ and present in an amount so as to be individually visible during implantation; and

radiopaque contrast particles [~~for contrast~~] having a particle size less than [~~up to about~~] 350μ wherein

said contrast particles enhance the visibility of said matrix, and

said radiopaque tracer particles visibly indicate flow of said matrix [~~to be individually visible~~] during implantation [~~are larger than said radiopaque for contrast~~].

41. (Currently amended) The injectable composition of claim 40, wherein said radiopaque tracer particles have a size between about 570μ and 2200μ.

42. (Currently amended) The injectable composition of claim 40, wherein said radiopaque tracer particles have a size between about 450μ and 1600μ.

43. (Currently amended) The injectable composition of claim 40, wherein said radiopaque tracer particles have a size between about 570μ and 1150μ.

44. (Currently amended) The injectable composition of claim 40, wherein said radiopaque tracer particles for contrast are between about 120μ and 350μ.

45. (Canceled)

46. (Withdrawn) The injectable composition of claim 36, further comprising: radiopaque particles for contrast having a particle size up to about 350μ.

47. (Withdrawn) An injectable composition comprising:

a hard tissue implant biocompatible matrix; and

radiopaque particles mixed within said biocompatible matrix, said radiopaque particles having a particle size of about 120μ to about 2200μ.

48. (Withdrawn) The injectable composition of claim 47, wherein said biocompatible matrix and said radiopaque particles form a slurry.

49. (Withdrawn) The injectable composition of claim 47, wherein said radiopaque particles have a particle size between about 350μ and 2200μ.

50. (Withdrawn) The injectable composition of claim 47, wherein said radiopaque particles have a particle size between about 450μ and 1600μ.

51. (Withdrawn) The injectable composition of claim 50, wherein said radiopaque particles have a particle size between about 570μ and 1150μ.

52. (Withdrawn) The injectable composition of claim 49, further comprising: radiopaque particles for contrast having a particle size between 120μ and 350μ.

53. (Withdrawn) The injectable composition of claim 49, further comprising: radiopaque particles for contrast having a particle size up to about 350μ.

54. (New) The injectable composition of claim 40, wherein the matrix is selected from the group consisting of polymethyl methacrylate, hydroxyapatite, various formulations of biocompatible calcium phosphates, biocompatible calcium sulfates, demineralized and/or mineralized bone particles, polymer based implants including polyglycolic acid and/or polylactic acid compounds, collagen and/or collagen derivative preparations alone or in combination with other biomaterials, chitin and/or chitosan preparations, bioglasses including oxides of silicon,

sodium, calcium and phosphorous and combinations thereof, and other known materials which are acceptable for use as hard tissue implant materials including osteogenic and osteoinductive compositions, and combinations thereof.

55. (New) The injectable composition of claim 40, wherein the radiopaque tracer particles is selected from the group consisting of barium sulfate, tungsten, tantalum, zirconium, platinum, gold, silver, stainless steel, titanium, alloys thereof, combinations thereof, and equivalent materials used as radiographic agents in hard tissue implant materials that can be formed as particles.

56. (New) The injectable composition of claim 40, wherein the radiopaque contrast particles is selected from the group consisting of barium sulfate, bismuth subcarbonate, bismuth sulfate, powdered tungsten, powdered tantalum, zirconium, combinations thereof, and equivalent materials for use as radiographic agents in hard tissue implant materials that can be formed as particles.

57. (New) The injectable composition of claim 56, wherein the radiopaque contrast particle is selected from the group consisting of a liquid contrast agent, a soluble contrast agents and metrizamide.

58. (New) The injectable composition of claim 40, wherein the matrix and radiopaque tracer particles comprise a slurry.

59. (New) The injectable composition of claim 58, wherein the slurry comprises an injectable composition for hard tissue implantation.

60. (New) The injectable composition of claim 40, wherein the radiopaque tracer particles comprises from about 1% to about 10% of the total weight of the composition.

61. (New) The injectable composition of claim 60, wherein the radiopaque tracer particles comprises a mixture of barium sulphate and tungsten particles.

62. (New) An injectable composition comprising:

a flowable matrix; and

radiopaque tracer particles,

wherein the size of the radiopaque tracer particles is substantially between 350μ and 2200μ and wherein the amount of radiopaque tracer particles present is sufficient to be individually visible during implantation to visible indicate flow of the matrix during implantation.

63. (New) The injectable composition of claim 62, comprising radiopaque contrast particles having a particle size less than 350μ wherein the contrast particles enhance the visibility of said matrix.

64. (New) The injectable composition of claim 62, wherein the flowable matrix is selected from the group consisting of polymethyl methacrylate, hydroxyapatite, various formulations of biocompatible calcium phosphates, biocompatible calcium sulfates, demineralized and/or mineralized bone particles, polymer based implants including polyglycolic acid and/or polylactic acid compounds, collagen and/or collagen derivative preparations alone or in combination with other biomaterials, chitin and/or chitosan preparations, bioglasses including oxides of silicon, sodium, calcium and phosphorous and combinations thereof, and other known materials which are acceptable for use as hard tissue implant materials including osteogenic and osteoinductive compositions, and combinations thereof.

65. (New) The injectable composition of claim 62, wherein the radiopaque tracer particles is selected from the group consisting of barium sulfate, tungsten, tantalum, zirconium, platinum, gold, silver, stainless steel, titanium, alloys thereof, combinations thereof, and equivalent materials used as radiographic agents in hard tissue implant materials that can be formed as particles.

66. (New) The injectable composition of claim 63, wherein the radiopaque contrast particles contrast particles is selected from the group consisting of barium sulfate, bismuth subcarbonate, bismuth sulfate, powdered tungsten, powdered tantalum, zirconium, combinations thereof, and equivalent materials for use as radiographic agents in hard tissue implant materials that can be formed as particles.

67. (New) The injectable composition of claim 62, wherein the amount of radiopaque tracer particles comprises from about 1% to about 10% of the total weight of the composition.

68. (New) The injectable composition of claim 62, wherein the radiopaque tracer particles are sized between about 570μ and 2200μ.

69. (New) The injectable composition of claim 62, wherein the radiopaque tracer particles are sized between about 450μ and 1600μ.

70. (New) The injectable composition of claim 40, wherein the radiopaque tracer particles are sized between about 570μ and 1150μ.

71. (New) The injectable composition of claim 40, wherein said radiopaque tracer particles for contrast are sized between about 120μ and 350μ.